Last reviewed · How we verify
NCT04822753
Platelet Rich Plasma (PRP) for Facet Mediated Lumbar Low Back Pain
NA trial testing Platelet Rich Plasma injection to the lumbar facet joint in Facet Joint Pain; Low Back Pain in 91 participants. Completed in 23 June 2025.
23 June 2025
Quick facts
| Lead sponsor | Womack Army Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 91 |
| Start date | 29 September 2021 |
| Primary completion | 23 June 2025 |
| Estimated completion | 23 June 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Platelet Rich Plasma injection to the lumbar facet joint
Conditions studied
- Facet Joint Pain; Low Back Pain — all drugs for Facet Joint Pain; Low Back Pain →
Sponsor
Womack Army Medical Center
Who can join
Adults 18 to 75, any sex, with Facet Joint Pain; Low Back Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Low back pain (LBP) is both the single most common cause of disability and the leading cause of visits when military personnel go to their primary care doctors. Military personnel that deal with LBP can often be placed on limited duty profile. Not surprisingly, the direct and indirect costs of low back and neck pain accounts for approximately $88 billion of health care expenditure. In order to reduce the large financial and personal cost, clinical studies must be designed to treat LBP. This study will provide evidence-based medicine on a new regenerative medicine treatment option that may significantly affect military personnel with LBP. PRP (Platelet Rich Plasma) may offer alternate treatment methods that may help preserve the facet joint structures, and improve pain and function without causing destructive lesions or worsening degenerative joints. This healing process may favor improved participation with rehabilitation therapy and ultimately improve return to duty status. This study will also assess the effectiveness of point of care generated PRP, as a minimally invasive treatment option for treating lumbar facet pain. Specifically, PRP effectiveness will be compared to injecting placebo control when injected into facet joints.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04822753
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Womack Army Medical Center trials
Trials by the same sponsor.
- NCT06527287 — Neurocognitive Ankle Training for Instability to Optimize Neuromusculoskeletal Outcomes (NATION) · NA · not yet recruiting
- NCT05111925 — Pre- and Post-neuromusculoskeletal Injury Risk Evaluation for Return-to-Duty Enhancement · recruiting
- NCT04163679 — Vaginal Preparation and Azithromycin to Reduce Post Cesarean Infections · NA · terminated
- NCT03184298 — Piloting ProHealth: A Program for Male Soldiers on Sex, Dating and Alcohol-Use at Fort Bragg · NA · unknown
- NCT03264326 — Efficacy of BFR Training Combined With Eccentric Exercise as Assessed by SWE in Subjects With Chronic AT · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04822753 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Womack Army Medical Center
- Last refreshed: 11 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04822753.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing